Document text
Principal Investigator: Barney Graham
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2019
Award: $3,806,087
Funding agency: National Institute of Allergy and Infectious Diseases
Improvements in vaccines against influenza that increase potency, breadth and duration of protection would improve worldwide ability to combat seasonal changes in influenza viruses (drift) and emergence of new pandemic strains (shift). This study aims to develop new platforms and vaccination strategies against influenza. Nanoparticle-, and nucleic acid-based vaccines have been developed against multiple seasonal and pandemic strains of influenza, including H7N9, and H5N1 avian influenza viruses. In addition, studies are ongoing to identify and optimize vaccine antigens to present conserved regions of the influenza virus hemagglutinin (HA) in order to develop a vaccine that provides broader universal protection. These include nanoparticle display of both group 1 and group 2 influenza HA stabilized stem trimers, as well as a collection of less-conserved HA head domains. Testing has been conducted to evaluate candidates, as well as adjuvants to boost immune response, and determine the optimal strategies for immunization. Several candidates showed promising results that lead to further evaluations, using DNA and DNA prime with inactivated vaccine boost or nanoparticles displaying full length, stem, and/or receptor-binding domain HA antigens. Multiple cycles of iterative structure-based design yielded a structurally stabilized trimer of the HA stem derived from H1N1 A/New Caledonia/20/1999, which belongs to group 1. Several versions of these immunogens were generated and tested its immunogenicity in animal models, as well as to co-crystallize with stem-binding monoclonal antibodies. Immunization with these nanoparticles induces homologous and heterologous binding antibodies in mice and ferrets with low levels of neutralizing antibodies. Despite this relatively weak neutralizing activity, immunization confers complete protection in mice and near-complete protection in ferrets from heterosubtypic H5N1 lethal influenza challenge. Passive transfer of immunoglobulins from immunized mice provides protection against lethal H5 challenge in recipient mice, indicating the protection is antibody-mediated. Further studies to determine the immunological basis of protection are underway, as well as efforts to improve the group 1 immunogen to increase neutralizing responses. Group 2 designs have also been advanced through in vitro characterizations, animal studies and product development, and a lead candidate is now in GMP manufacturing. In addition, collaborations to develop gene-based vaccine platforms such as mRNA platform are underway. The first-in-human influenza HA nanoparticle vaccine clinical trial is nearly complete, and the Phase 1 clinical trial testing the H1 stem ferritin immunogen is currently enrolling. The Phase 1 trial utilizing the group 2 stem immunogen is expected to open in spring 2020. Collaborations have been established to design novel multi-component nanoparticles, and the first candidate shows promising immunogenicity results in animal models and is being transferred into advanced product development. The design program utilizing viral neuraminidase (NA) initiated last year continues, with progress made on reagents, assays, and candidate immunogens for testing in animal models. Collaborations are in progress to pair vaccine candidates with advanced adjuvants in Phase 1 clinical trials.
Terms: <ATGN><Acylneuraminyl hydrolase><Adjuvant><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigens><Assay><Binding><Bioassay><Biologic Assays><Biological Assay><Bird Flu vaccine><Clinical Treatment Moab><Collaborations><Collection><Crystallization><DNA><Deoxyribonucleic Acid><Early-Stage Clinical Trials><Enrollment><Evaluation><Ferrets><Ferritin><Genes><Goals><Grippe><H1N1><H1N1 Virus><H5N1><H5N1 virus><H7N9><Head><Hemagglutinin><Immune Globulins><Immune response><Immunization><Immunize><Immunochemical Immunologic><Immunoglobulins><Immunologic><Immunologic Sensitization><Immunologic Stimulation><Immunological><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologically><Immunologics><Immunostimulation><In Vitro><Inactivated Vaccines><Inactivated Virus Vaccine><Influenza><Influenza A Virus, H1N1 Subtype><Influenza A Virus, H5N1 Subtype><Influenza A Virus, H7N9 Subtype><Influenza HA><Influenza Hemagglutinin><Influenza Vaccines><Influenza Virus><Killed Vaccines><Lead><Length><Mediating><Messenger RNA><Methodology><Mice><Mice Mammals><Molecular Interaction><Monoclonal Antibodies><Murine><Mus><N-Acylneuraminate Glycohydrolases><Neuraminidase><New Caledonia><Nucleic Acids><Oligosaccharide Sialidase><Pb element><Phase 1 Clinical Trials><Phase I Clinical Trials><Production><Public Health><Reagent><Sialidase><Structure><Testing><Time><Vaccine Antigen><Vaccine Clinical Trial><Vaccines><Viral><avian flu vaccine><avian influenza H5N1><avian influenza H5N1 virus><avian influenza vaccine><base><combat><design><designing><develop a vaccine><development of a vaccine><enroll><exo alpha sialidase><first in man><first-in-human><flu HA><flu hemagglutinin><flu infection><flu vaccine><flu virus vaccine><heavy metal Pb><heavy metal lead><host response><human subject><immunogen><immunogenicity><immunoresponse><improved><influenza infection><influenza virus HA><influenza virus hemagglutinin><influenza virus vaccine><influenzavirus><lead candidate><mAbs><mRNA><model of animal><model organism><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><novel><pandemic><pandemic disease><pandemic flu><pandemic influenza><pandemic strain of influenza><phase 1 trial><phase I protocol><product development><programs><receptor binding><receptor bound><response><seasonal flu><seasonal influenza><stem><tool><universal flu vaccine><universal influenza vaccine><vaccination strategy><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine development><vaccine formulation>